Research across Embolism and Thrombosis
Related studies from across the Embolism and Thrombosis family.
Part of Embolism and Thrombosis
2 published articles · Updated continuously
10 trials tracked for branch retinal vein occlusion: 6 in phase 3 or 4 and 3 with published results. The most-cited published study has 119 citations.
Showing the 10 most-cited and recently-updated of 10 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Several anti-VEGF agents have demonstrated efficacy in treating branch retinal vein occlusion (BRVO). Ranibizumab showed significant improvements in Best Corrected Visual Acuity (BCVA), with mean changes ranging from 16.18 to 74.3 letters depending on the study cohort [3, 6]. In one large trial, Ranibizumab resulted in a high percentage of patients achieving gains of $\geq$15 letters by month 6 3, while another trial showed 77% of patients gained $\geq$15 letters over 6 months 6.
Aflibercept demonstrated significant clinical improvements for BRVO. Patients treated with Aflibercept showed a mean BCVA increase of 18.4 1 and a statistically significant gain in the percentage of participants achieving $\geq$15 letters in BCVA at week 24 compared to placebo (p=0.0003) along with a significant reduction in central retinal thickness (CRT) 5.
Other interventions include pegaptanib sodium, which showed a mean change in BCVA of 14 and a reduction in macular thickening measured by OCT3 (-205) 2. Faricimab was evaluated for BRVO; while it showed improvements in BCVA over 24 weeks (ranging from 11.5 to 15.9), the difference between treatment arms at week 24 did not reach statistical significance (p=0.4978) 4.
Ranibizumab was also evaluated in a smaller cohort of 12 patients, confirming its use in this condition 8.
AI synthesis of 7 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
Related studies from across the Embolism and Thrombosis family.